What targeted drugs should be taken after resistance to dacomitinib?

Dacomitinib (Dacomitinib) is an oral targeted drug commonly used to treat non-small cell lung cancer. Dacomitinib is an orally active pan-HER family inhibitor in clinical models and is active against EGFR, HER2 and HER4. However, some patients may develop resistance to dacomitinib for various reasons. When a patient develops drug resistance, choosing the next treatment option often requires individualized assessment and decision-making.

For patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations L858R or del19, the drugs osimertinib, afatinib, gefitinib or erlotinib are treatment options. For example, osimertinib is an adjuvant treatment suitable for adult patients with non-small cell lung cancer after tumor resection, and is also used as a first-line treatment for adult patients with metastatic non-small cell lung cancer with this mutation. This is based on current clinical practice and research results. Since everyone’s physique is different and their resistance to drugs is also different, please inform your doctor in time if you feel unwell.

The original drug of dacomitinib has been launched in China and has entered the scope of Class B medical insurance. The price of the common specification 15mg*30 tablets per box may be more than 1,000 yuan; the European version of dacomitiniboriginal drug sold overseas, the specification 45mg*30 tablets may be more than 20,000 yuan per box (the price may fluctuate due to exchange rates). Currently, there are cheaper generic drugs of dacomitinib sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 45mg*30 tablets produced by a Lao pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to exchange rate effects).